Home / Business and Economy / Eli Lilly Nears $2B+ Deal for Gene Therapy Firm
Eli Lilly Nears $2B+ Deal for Gene Therapy Firm
20 Apr
Summary
- Eli Lilly is in advanced talks to acquire Kelonia Therapeutics.
- The deal for Kelonia Therapeutics is valued at over $2 billion.
- Kelonia Therapeutics specializes in genetic medicines and CAR-T therapies.
U.S. pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire Kelonia Therapeutics, a clinical-stage biotechnology company. The potential deal is valued at more than $2 billion, with negotiations possibly concluding as early as Monday.
Kelonia Therapeutics, based in Boston, focuses on developing genetic medicines, including CAR-T cell therapies, for a range of diseases. CAR-T therapies are designed to modify a patient's immune cells to target and eliminate cancer cells.
This prospective acquisition would significantly enhance Eli Lilly's cancer treatment offerings, adding to its existing pipeline that includes therapies like Jaypirca and Verzenio. The move aims to strengthen Lilly's competitive position in the rapidly growing oncology market.
Eli Lilly, already a dominant player in the obesity market with its blockbuster drugs, is actively diversifying its therapeutic focus. The company is expanding into areas such as inflammatory bowel disease, cancer, eye disorders, and gene-editing technologies through strategic acquisitions and partnerships. Notably, Lilly recently agreed to acquire Orna Therapeutics for up to $2.4 billion.
